Drugs that were primarily developed for sarcoma by our criteria included trabectedin (DNA alkylating agent, DNA minor groove binder that inhibits oncogenic FUS‐CHOP transcription factor), brostallicin (DNA alkylating agent), trofosfamide (alkylating agent), mithramycin (RNA synthesis inhibitor), conatumumab (antibody against TRAIL receptor 2), and the SYT‐SSX junction peptide vaccine (specific synovial sarcoma fusion protein vaccine). This evidence concerns the gene FUS and sarcoma.